Alzheimer's Disease: A Comprehensive Review of Pathogenesis, Diagnostic Biomarkers, Clinical Progression, and Evolving Therapeutics

Alzheimer's disease (AD) is the major cause of dementia worldwide and a progressive neurodegenerative disorder, accounting for 60–70% of the estimated 55 million global cases of dementia. The core neuropathological hallmarks, extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs) of hyperphosphorylated tau, activate a complex pathophysiological cascade including chronic neuroinflammation, reactive microgliosis, astrocytic dysfunction, mitochondrial failure, oxidative stress, synaptic breakdown and extensive neuronal loss. The historical reliance on late-stage syndromic definitions has now been replaced by a rigorous biological framework (Revised 2024 Criteria and AT (N) staging), enabling disease identification years prior to overt dementia via cerebrospinal fluid (CSF) assays, molecular positron emission tomography (PET), and increasingly studied blood-based biomarkers such as plasma phosphorylated-tau217 (p-tau217). Conventional pharmacotherapies (acetylcholinesterase inhibitors and memantine) provide modest symptomatic stabilization without altering disease pathology. In contrast, recently approved disease-modifying monoclonal antibodies (lecanemab and donanemab) clear cerebral amyloid plaques and modestly slow cognitive and functional decline in early symptomatic stages. But these therapies have clinical challenges including amyloid-related imaging abnormalities (ARIA), high cost and infrastructure needs. At the same time, multi-domain non-pharmacological approaches, such as structured physical exercise, cognitive stimulation, nutritional optimization and caregiver support, continue to be fundamental pillars of holistic care. This review summarizes the current evidence for the epidemiology of AD, its multifactorial etiology, molecular pathophysiology, clinical course, biological diagnostic criteria, evidence-based pharmacotherapies and emerging precision therapeutics.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-12
DOI
https://doi.org/10.5281/zenodo.24152887
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Alzheimer's Disease: A Comprehensive Review of Pathogenesis, Diagnostic Biomarkers, Clinical Progression, and Evolving Therapeutics

Rupali Karale, Chaitanya Patil, Ashish Jamghare, Abhilasha Gambhirao et al.
Zenodo (CERN European Organization for Nuclear Research)
Alzheimer's disease research and treatments
article

Alzheimer's Disease: A Comprehensive Review of Pathogenesis, Diagnostic Biomarkers, Clinical Progression, and Evolving Therapeutics

Rupali Karale, Chaitanya Patil, Ashish Jamghare, Abhilasha Gambhirao, Saniya Shelar, Raj Khateghare
article en

Abstract

Alzheimer's disease (AD) is the major cause of dementia worldwide and a progressive neurodegenerative disorder, accounting for 60–70% of the estimated 55 million global cases of dementia. The core neuropathological hallmarks, extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs) of hyperphosphorylated tau, activate a complex pathophysiological cascade including chronic neuroinflammation, reactive microgliosis, astrocytic dysfunction, mitochondrial failure, oxidative stress, synaptic breakdown and extensive neuronal loss. The historical reliance on late-stage syndromic definitions has now been replaced by a rigorous biological framework (Revised 2024 Criteria and AT (N) staging), enabling disease identification years prior to overt dementia via cerebrospinal fluid (CSF) assays, molecular positron emission tomography (PET), and increasingly studied blood-based biomarkers such as plasma phosphorylated-tau217 (p-tau217). Conventional pharmacotherapies (acetylcholinesterase inhibitors and memantine) provide modest symptomatic stabilization without altering disease pathology. In contrast, recently approved disease-modifying monoclonal antibodies (lecanemab and donanemab) clear cerebral amyloid plaques and modestly slow cognitive and functional decline in early symptomatic stages. But these therapies have clinical challenges including amyloid-related imaging abnormalities (ARIA), high cost and infrastructure needs. At the same time, multi-domain non-pharmacological approaches, such as structured physical exercise, cognitive stimulation, nutritional optimization and caregiver support, continue to be fundamental pillars of holistic care. This review summarizes the current evidence for the epidemiology of AD, its multifactorial etiology, molecular pathophysiology, clinical course, biological diagnostic criteria, evidence-based pharmacotherapies and emerging precision therapeutics.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon